GlassScriptPhysician profile
Kibbum Kang
NPI 1548502347
$2,017.33
in general payments reported to CMS, 2019-2025
20 companies · $1,061 in 2025
The $1,061 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.17 · 2023: $292 · 2024: $637 · 2025: $1,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,946 · Education: $43.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,946.23 |
| Education | $43.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $531.12 | 2023-2025 | |
| Janssen Biotech, INC. | $302.01 | 2024-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $207.29 | 2024-2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $177.46 | 2021-2025 | Xifaxan |
| Gilead Sciences, INC. | $122.03 | 2025 | Livdelzi |
| Genzyme Corporation | $88.26 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $87.97 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $86.40 | 2024-2025 | Ibsrela |
| Celltrion USA INC. | $73.05 | 2024-2025 | Zymfentra, Vegzelma |
| Celgene Corporation | $64.22 | 2023-2024 | Zeposia |
| Qol Medical, LLC | $57.96 | 2025 | Sucraid |
| Lilly USA, LLC | $42.48 | 2024-2025 | Omvoh |
| Novo Nordisk INC | $29.43 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $27.20 | 2025 | Iqirvo |
| Pfizer INC. | $24.90 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $23.35 | 2025 | Entyvio |
| Nestle Healthcare Nutrition INC. | $20.38 | 2023 | |
| Ethicon US, LLC | $20.33 | 2024 | Linx Reflux Management System |
| Ironwood Pharmaceuticals, INC | $18.49 | 2023 | Linzess |
| Intercept Pharmaceuticals, INC. | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kibbum Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.